Another study also supported the use of ACEi/ARB in improving clinical outcomes of COVID-19 patients with hypertension, as they found that using ACEi/ARB could significantly reduce the level of interleukin 6 while increasing the level of peripheral blood T cells (26). Here, IL6 is linked to COVID-19.